{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:45:24Z","timestamp":1789008324471,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011494","name":"Baoding City Science and Technology and Intellectual Property Bureau","doi-asserted-by":"publisher","award":["2441ZF218"],"award-info":[{"award-number":["2441ZF218"]}],"id":[{"id":"10.13039\/501100011494","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmc.2025.118394","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T18:09:05Z","timestamp":1758132545000},"page":"118394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of N-(4-(pyridin-4-yloxy)phenyl)-1,2-dihydropyridine-3-carboxamide derivatives as potential type II c-Met inhibitors"],"prefix":"10.1016","volume":"131","author":[{"given":"Qingwang","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojian","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jikang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118394_bb0005","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1200\/JCO.2012.43.9422","article-title":"Met as a possible target for non-small-cell lung cancer","volume":"31","author":"Sadiq","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2025.118394_bb0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting met in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2025.118394_bb0015","first-page":"501","article-title":"Hepatocyte growth factor (hgf) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-met","volume":"6","author":"Naldini","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2025.118394_bb0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2025.118394_bb0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4161\/cam.4.1.10973","article-title":"Met molecular mechanisms and therapies in lung cancer","volume":"4","author":"Lawrence","year":"2010","journal-title":"Cell Adhes Migr"},{"key":"10.1016\/j.bmc.2025.118394_bb0030","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","article-title":"Targeting met dysregulation in cancer","volume":"10","author":"Recondo","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2025.118394_bb0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","article-title":"Resistance mechanisms to osimertinib in egfr-mutated advanced non-small-cell lung cancer: a multicentric retrospective french study","volume":"137","author":"Mehlman","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bmc.2025.118394_bb0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"Azd9291, an irreversible egfr tki, overcomes t790m-mediated resistance to egfr inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2025.118394_bb0045","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with egfr-mutated advanced non-small cell lung cancer from the aura3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118394_bb0050","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-CT033","article-title":"Abstract ct033: Tatton phase ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with egfr-mutant, met-amplified nsclc after progression on prior third-generation epidermal growth factor receptor (egfr) tyrosine kinase inhibitor (tki)","volume":"79","author":"Sequist","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118394_bb0055","volume":"79","author":"Yu","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118394_bb0060","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (pf-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-met) kinase and anaplastic lymphoma kinase (alk)","volume":"54","author":"Cui","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118394_bb0065","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","article-title":"A novel kinase inhibitor, incb28060, blocks c-met-dependent signaling, neoplastic activities, and cross-talk with egfr and her-3","volume":"17","author":"Liu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118394_bb0070","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1158\/1078-0432.CCR-12-3247","article-title":"Emd 1214063 and emd 1204831 constitute a new class of potent and highly selective c-met inhibitors","volume":"19","author":"Bladt","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118394_bb0075","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"Jia","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118394_bb0080","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/acsmedchemlett.9b00276","article-title":"Structural and molecular insight into resistance mechanisms of first generation cmet inhibitors","volume":"10","author":"Collie","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118394_bb0085","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/2159-8290.CD-16-0686","article-title":"Acquired metd1228v mutation and resistance to met inhibition in lung cancer","volume":"6","author":"Bahcall","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2025.118394_bb0090","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jtho.2017.02.017","article-title":"Mutation of met y1230 as an acquired mechanism of crizotinib resistance in nsclc with met exon 14 skipping","volume":"12","author":"Schrock","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bmc.2025.118394_bb0095","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (xl184), a novel met and vegfr2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2025.118394_bb0100","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10637-012-9912-9","article-title":"Ly2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against met, mst1r, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models","volume":"31","author":"Yan","year":"2013","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.bmc.2025.118394_bb0105","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.1021\/acs.jmedchem.7b00794","article-title":"Dual met and smo negative modulators overcome resistance to egfr inhibitors in human nonsmall cell lung cancer","volume":"60","author":"Morgillo","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118394_bb0110","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1021\/acs.jmedchem.3c00028","article-title":"Targeting met: discovery of small molecule inhibitors as non-small cell lung cancer therapy","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118394_bb0115","doi-asserted-by":"crossref","first-page":"8782","DOI":"10.1021\/acs.jmedchem.3c00401","article-title":"Discovery and optimization of the first atp competitive type-iii c-met inhibitor","volume":"66","author":"Michaelides","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118394_bb0120","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/jm801586s","article-title":"Discovery of n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (bms-777607), a selective and orally efficacious inhibitor of the met kinase superfamily","volume":"52","author":"Schroeder","year":"2009","journal-title":"J Med Chem"}],"updated-by":[{"DOI":"10.1016\/j.bmc.2025.118524","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000}},{"DOI":"10.1016\/j.bmc.2025.118524","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:35:27Z","timestamp":1780403727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625003359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"alternative-id":["S0968089625003359"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118394","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of N-(4-(pyridin-4-yloxy)phenyl)-1,2-dihydropyridine-3-carboxamide derivatives as potential type II c-Met inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118394"}}